Re: BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer

in response to

Re: BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer

tada

posted on Feb 06, 2019 09:52AM

Some journals are open access, others require an individual or institution subscription. It's not an issue of Pubmed but the individual journals.